sponsored
PatientsVille.com Logo

PatientsVille

Portal Medical Research Studies

Up-to-date List of Portal Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Portal Medical Research Studies

Rank Status Study
1 Recruiting Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus;   Drug: Sandostatin LAR Depot
Outcome Measures: Number of patients receiving everolimus;   Number of patients experiencing serious adverse events
2 Recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Conditions: Influenza, Human;   Flu, Human;   Flu, Avian;   Influenza;   Influenza A Virus, H5N1 Subtype
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
Outcome Measures: Percentage of subjects achieving seroconversion*;   Geometric mean ratios (GMRs) as determined by HI assay;   Percentage of subjects with an HI titer ≥1:40;   Solicited and unsolicited adverse events;   Geometric mean titers as determined by Hemagglutination Inhibition;   Geometric mean titers as determined by Single Radial Hemolysis;   Geometric Mean Ratio as determined by Hemagglutination Inhibition;   Geometric Mean Ratio as determined by Single Radial Hemolysis;   Percentage of subjects achieving seroconversion determined by HI;   Percentage of subjects achieving seroconversion determined by SRH;   Percentage of subjects with geometric mean area ≥25 mm2
3 Recruiting Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Condition: Neoplasms
Intervention: Drug: Everolimus
Outcome Measure: Number of pariticipants with Adverse events as a measure of safety and tolerability
4 Recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107
Outcome Measures: Number of patients receiving nilotinib;   Frequency of serious adverse events;   Nature of serious adverse events
5 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
Outcome Measures: Number of patients receiving pasireotide;   Frequency and nature of serious adverse events (SAEs)
6 Recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
Outcome Measures: Number of patients receiving imatinib;   Frequency and nature of serious adverse events
7 Not yet recruiting An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Condition: Solid Tumors
Intervention: Drug: dovitinib
Outcome Measure: Incidence and severity of adverse events
8 Recruiting Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: Hematologic Neoplasms
Intervention: Drug: Panobinostat
Outcome Measures: Number of patients receiving single agent panobinostat;   Number fo patients experiencing Serious Adverse Events (SAEs)
9 Recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Conditions: Influenza,;   Flu,
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
Outcome Measures: Percentage of subjects achieving seroconversion;   Geometric mean ratios (GMRs) as determined by HI assay;   Percentage of subjects with an HI titer ≥1:40;   Solicited and unsolicited adverse events;   Geometric mean titers (GMTs) as determined by HI;   Geometric mean ratios (GMRs) as determined by SRH;   Percentage of subjects with geometric mean area ≥25 mm2;   GMTs as determined by SRH;   GMRs as determined by HI;   GMRs as determined by SRH
10 Recruiting Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
Condition: Meningococcal Disease
Intervention: Biological: rMenB+OMV
Outcome Measures: hSBA GMT, GMR, percentage of subjects with hSBA titers ≥5 and ≥ 8 against serogroups B indicator strains and ELISA GMC, GMR for vaccine antigen 287-953;   percentage of subject with four-fold increase in hSBA titers against serogroups B indicator strains and in ELISA concentration for vaccine antigen 287-953;   Frequencies and percentage of subjects with solicited AE unsolicited AE, medically attended AEs, AEs leading to withdrawn and SAEs
11 Not yet recruiting Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV and MenACWY;   Biological: rMenB+OMV;   Biological: MenACWY
Outcome Measures: Between-group ratios of hSBA Geometric Mean Titers (GMTs) for all serogroups B (all indicator strains), A, C, W-135 and Y.;   hSBA GMT, percentage of subjects with hSBA ≥1:5 and percentage of subjects with hSBA ≥ 1:8 against serogroups B (all indicator strains), A, C, W-135 and Y;   Within subject Geometric Mean Ratios (GMRs) and percentage of subject with four-fold increase in hSBA titers, at one months after fourth vaccination versus pre-fourth vaccination;   Percentage of subjects with solicited AE, unsolicited AE, medically attended AEs, AEs leading to withdrawn and SAEs
12 Recruiting Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 to 55 Years of Age in the Republic of South Korea
Condition: Meningococcal Disease
Intervention: Biological: Novartis Meningococcal ACWY Conjugate Vaccine
Outcome Measures: Safety of a single dose of MenACWY-CRM vaccine in subjects from 2 to 55 years of age, as evaluated by local and systemic solicited Adverse Events;   Safety of a single dose of MenACWY-CRM vaccine in subjects from 2 to 55 years of age, as evaluated by all Unsolicited Adverse Events;   Safety of a single dose of MenACWY-CRM vaccine in subjects from 2 to 55 years of age, as evaluated by Medically attended Adverse Events and Serious Adverse Events
13 Recruiting Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
Condition: Chronic Obstructive Pulmonary Disease: COPD
Interventions: Drug: QAB149;   Drug: Placebo;   Drug: NVA237
Outcome Measures: Inspiratory Capacity (IC) peak value;   Forced Expiratory Volume in one second (FEV1);   Inspiratory Capacity (IC);   Forced Volume Capacity (FVC);   Total Lung Capacity (TLC);   Airway Resistance (Raw)
14 Recruiting Fructans, Lactitol and Lactose in Minimal Hepatic Encephalopathy
Condition: Liver Cirrhosis
Interventions: Dietary Supplement: Red cereal bar;   Dietary Supplement: Green cereal bar;   Dietary Supplement: White cereal bar
Outcome Measures: Minimal hepatic encephalopathy;   Nutritional Status
15 Recruiting A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
Condition: Influenza (Seasonal)
Interventions: Biological: Novartis MF59-adjuvanted influenza subunit vaccine;   Biological: Sandoz Korea MF59-adjuvanted influenza subunit vaccine
Outcome Measures: Occurrence of solicited local (tenderness, erythema, induration, swelling and pain at the injection site) and systemic reactions (chills, myalgia, arthralgia, headache, sweating, fatigue and fever);   Occurrence of unsolicited adverse events;   Occurrence of serious adverse events
16 Recruiting Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Tiotropium;   Drug: placebo
Outcome Measures: overall serious adverse event rate;   Composite endpoint of all-cause mortality and serious cerebro-cardiovascular events;   Electrocardiogram;   Health Status as measured by St. George's Respiratory Questionnaire for COPD patients (SGRQ-C);   Daily, morning and evening symptom scores;   Percentage of nights with 'no nighttime awakenings';   Percentage of days with 'no daytime symptoms';   Percentage of 'days able to perform usual daily activities';   Pre-Dose forced expiratory volume over in second (FEV1);   Pre-Dose forced vital capacity (FVC);   Post dose forced expiratory volume in one second (FEV1);   Post Dose forced vital capacity (FVC);   Time to discontinuation;   Vital Signs;   Lab values
17 Recruiting QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: QVA149;   Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
Outcome Measures: Rate of COPD exacerbations;   Time to first COPD exacerbation.;   Rate of moderate to severe COPD exacerbations.;   Time to first moderate to severe COPD exacerbation.;   Rate of moderate to severe COPD exacerbations requiring treatment with systemic corticosteroids;   Rate of moderate to severe COPD exacerbations requiring treatment with antibiotics;   Rate of moderate to severe COPD exacerbations requiring hospitalization.;   Rate of moderate to severe COPD exacerbations requiring re-hospitalization within 30 days;   Time to first moderate to severe COPD exacerbations requiring treatment with systemic corticosteroids;   Time to first moderate to severe COPD exacerbations requiring treatment with antibiotics;   Time to first moderate to severe COPD exacerbations requiring hospitalization;   Time to first moderate to severe COPD exacerbations requiring re-hospitalization within 30 days;   Forced expiratory volume in 1 second;   Forced expiratory volume in 1 second AUC (0-12h);   Total St. George's Respiratory Questionnaire score;   Number of puffs of rescue medication
18 Recruiting Comparison of Indacaterol 150 μg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 μg/500 μg Twice Daily (b.i.d.)
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol;   Drug: Salmeterol
Outcome Measures: Trough forced expiratory volume in one second (FEV1) at 12 weeks;   Trough FEV1;   FEV1;   FVC;   Standardized AUC (5min-4h) for FEV1;   Transition Dyspnea Index;   COPD Exacerbations;   Mean daily rescue medication use;   Percentage of days with no rescue medication use;   St Georges Respiratory Questionnaire for COPD;   Adverse event data;   ECG;   Vital signs;   Biochemistry, haematology, urinalysis data
19 Recruiting Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
Condition: Acute Leukemias
Intervention: Drug: LDE225
Outcome Measures: Rate of complete remission (CR) and complete remission with incomplete blood count recovery (CRi);   Overall Response Rate (ORR) on two different dosing schedules of LDE225 in acute leukemia;   Safety and tolerability of two different dosing schedules of LDE225 in acute leukemia;   Characterization of the pharmacokinetics (PK) of two different dosing schedules of LDE225
20 Not yet recruiting Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
Condition: Meningococcal Disease
Interventions: Biological: MenABCWY;   Biological: MenACWY
Outcome Measures: Percentages of N. meningitidis serogroup B invasive disease strains killed at 1:4 and 1:8 dilutions, for each subject;   percentages of subjects with hSBA ≥ 1:4 and hSBA titer ≥ 1:8 against four N. meningitidis serogroup B test strains;   percentages of subjects with hSBA titers against serogroup B test strains ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128;   Adverse events and other indicators of reactogenicity;   percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroup B test strains;   hSBA Geometric Mean Titers against serogroup B test strains;   percentages of subjects with hSBA titers ≥ LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against serogroups A, C, W, Y;   percentages of subjects with two-, three- and four-fold rise in hSBA titer against serogroups A, C, W and Y;   hSBA Geometric Mean Titers to serogroups A, C, W, and Y

These studies may lead to new treatments and are adding insight into Portal etiology and treatment.

A major focus of Portal research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Portal